nalmefene hydrochloride · Indivior · NDA 217470
Opvee
Earliest generic entry, as listed
4 Aug 2042
Blocked by patent: US 12290596. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12290596 | use U-4182 · sets the listed date | 4 Aug 2042 |
| US 11458091 | drug product, use U-3630 | 10 Jul 2038 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217470 · 001 · RLD | spray, nasal | EQ 2.7MG BASE/SPRAY | 4 Aug 2042 |
Expired or delisted (1)
- NP · 22 May 2026